Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "ED"

8072 News Found

Gland Pharma receives approval for Edaravone Injection
Drug Approval | May 09, 2024

Gland Pharma receives approval for Edaravone Injection

The product is used to treat amyotrophic lateral sclerosis


Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr
News | May 09, 2024

Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr

The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024


AstraZeneca’s Calquence combination regimen demonstrated positive results in 1st-line mantle cell lymphoma in ECHO Phase III trial
Diagnostic Center | May 08, 2024

AstraZeneca’s Calquence combination regimen demonstrated positive results in 1st-line mantle cell lymphoma in ECHO Phase III trial

First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting


Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr
News | May 07, 2024

Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr

The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024


Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US
Drug Approval | May 06, 2024

Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US

ORACEA is a trademark of Galderma Holdings, S.A.


Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs
News | May 04, 2024

Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs

The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024


Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
News | May 04, 2024

Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr

The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024


Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
News | May 04, 2024

Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr

The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024


Wipro to implement Independent Health’s Medicare prescription payment plan platform
Digitisation | May 04, 2024

Wipro to implement Independent Health’s Medicare prescription payment plan platform

Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions


AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024
Diagnostic Center | May 02, 2024

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD